NCI-H1651Homo sapiens (Human)Cancer cell line

Also known as: NCIH1651, H-1651, H1651

🤖 AI SummaryBased on 10 publications

Quick Overview

Human lung cancer cell line with known genetic alterations and drug sensitivity profiles.

Detailed Summary

The NCI-H1651 cell line is a human lung cancer cell line derived from a small cell lung cancer (SCLC) tumor. It is characterized by specific genetic alterations, including mutations in the RB1 gene and other key oncogenes, which contribute to its tumorigenic potential. This cell line has been extensively studied for its response to various therapeutic agents, making it a valuable model for understanding drug resistance mechanisms and developing targeted therapies. Research on NCI-H1651 has provided insights into the molecular pathways involved in SCLC progression and has been utilized in studies related to the identification of novel therapeutic targets and biomarkers. The cell line is also noted for its utility in investigating the role of cell polarity genes and their disruption in cancer development.

Research Applications

Drug sensitivity profilingMolecular pathway analysisTherapeutic target identificationCell polarity gene studies

Key Characteristics

RB1 gene mutationsSmall cell lung cancer originDrug resistance mechanismsCell polarity disruption
Generated on 6/17/2025

Basic Information

Database IDCVCL_1484
SpeciesHomo sapiens (Human)
Tissue SourceLung[UBERON:UBERON_0002048]

Donor Information

Age71
Age CategoryAdult
SexMale

Disease Information

DiseaseLung adenocarcinoma
LineageLung
SubtypeLung Adenocarcinoma
OncoTree CodeLUAD

DepMap Information

Source TypeATCC
Source IDACH-000893_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Cys176Tyr (c.527G>A)Unspecified-PubMed=21173094, PubMed=1373872
MutationSimpleNF1p.Arg997fs*15 (c.2990delG)Heterozygous-Unknown, Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
10,13
D13S317
11
D16S539
11
D18S51
16.3
D19S433
13
D21S11
31.2
D2S1338
24
D3S1358
17
D5S818
12,14
D7S820
8
D8S1179
14,15
FGA
24
Penta D
13
Penta E
12,16,17
TH01
8
TPOX
11
vWA
18
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

From clinical specimens to human cancer preclinical models -- a journey the NCI-cell line database-25 years later.

Aldige C.R., Wistuba I.I., Minna J.D.

J. Cell. Biochem. 121:3986-3999(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Chemistry-first approach for nomination of personalized treatment in lung cancer.

Posner B.A., Minna J.D., Kim H.S., White M.A.

Cell 173:864-878.e29(2018).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Heymach J.V.

Cancer Discov. 2:798-811(2012).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Zhou X.-M., Gygi S.P., Gu T.-L., Polakiewicz R.D., Rush J., Comb M.J.

Cell 131:1190-1203(2007).

Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer.

Modi S., Kubo A., Oie H.K., Coxon A.B., Rehmatulla A., Kaye F.J.

Oncogene 19:4632-4639(2000).

NCI-Navy Medical Oncology Branch cell line data base.";

Carney D.N., Minna J.D., Mulshine J.L.

J. Cell. Biochem. Suppl. 24:32-91(1996).

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Gazdar A.F.

Oncogene 7:171-180(1992).

Web Resources